Effectiveness of third- or later-line therapy in patients with HER2-positive advanced gastric cancer: Results from an observational retrospective study in Japan

被引：1
|
作者：
Omori, Takeshi
Sakai, Daisuke
Fumita, Soichi
Fujita, Junya
Kawabata, Ryohei
Matsuyama, Jin
Yasui, Hisateru
Hirao, Motohiro
Kawase, Tomono
Kishi, Kentaro
Taniguchi, Hirokazu
Miyazaki, Yasuhiro
Miura, Tomoko
Miyake, Akimitsu
Kurokawa, Yukinori
Yamasaki, Makoto
Yamada, Tomomi
Satoh, Taroh
Eguchi, Hidetoshi
Doki, Yuichiro
机构：
[1] Osaka Int Canc Inst, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Suita, Osaka, Japan
[3] Kindai Univ, Osaka, Japan
[4] Sakai City Med Ctr, Sakai, Osaka, Japan
[5] Osaka Rosai Hosp, Sakai, Osaka, Japan
[6] Higashiosaka City Med Ctr, Higashiosaka, Osaka, Japan
[7] Kobe City Med Ctr, Gen Hosp, Kobe, Hyogo, Japan
[8] Natl Hosp Org Osaka Natl Hosp, Osaka, Japan
[9] Toyonaka City Hosp, Toyonaka, Osaka, Japan
[10] Osaka Police Hosp, Osaka, Japan
[11] Saiseikai Senri Hosp, Suita, Osaka, Japan
[12] Osaka Gen Med Ctr, Dept Surg, Osaka, Japan
[13] Daiichi Sankyo Co Ltd, Tokyo, Japan
[14] Osaka Univ Hosp, Suita, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.277
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
277
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study
    Sakai, Daisuke
    Omori, Takeshi
    Fumita, Soichi
    Fujita, Junya
    Kawabata, Ryohei
    Matsuyama, Jin
    Yasui, Hisateru
    Hirao, Motohiro
    Kawase, Tomono
    Kishi, Kentaro
    Taniguchi, Yoshiki
    Miyazaki, Yasuhiro
    Kawada, Junji
    Satake, Hironaga
    Miura, Tomoko
    Miyake, Akimitsu
    Kurokawa, Yukinori
    Yamasaki, Makoto
    Yamada, Tomomi
    Satoh, Taroh
    Eguchi, Hidetoshi
    Doki, Yuichiro
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1154 - 1163
  • [2] Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study
    Daisuke Sakai
    Takeshi Omori
    Soichi Fumita
    Junya Fujita
    Ryohei Kawabata
    Jin Matsuyama
    Hisateru Yasui
    Motohiro Hirao
    Tomono Kawase
    Kentaro Kishi
    Yoshiki Taniguchi
    Yasuhiro Miyazaki
    Junji Kawada
    Hironaga Satake
    Tomoko Miura
    Akimitsu Miyake
    Yukinori Kurokawa
    Makoto Yamasaki
    Tomomi Yamada
    Taroh Satoh
    Hidetoshi Eguchi
    Yuichiro Doki
    [J]. International Journal of Clinical Oncology, 2022, 27 : 1154 - 1163
  • [3] Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study
    Shimozaki, Keitaro
    Nakayama, Izuma
    Takahari, Daisuke
    Nagashima, Kengo
    Yoshino, Koichiro
    Fukuda, Koshiro
    Fukuoka, Shota
    Osumi, Hiroki
    Ogura, Mariko
    Wakatsuki, Takeru
    Ooki, Akira
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    [J]. JOURNAL OF GASTRIC CANCER, 2023, 23 (04) : 609 - 621
  • [4] Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A single-institution retrospective study.
    Shimozaki, Keitaro
    Nakayama, Izuma
    Takahari, Daisuke
    Nagashima, Kengo
    Yoshino, Koichiro
    Fukuda, Koshiro
    Fukuoka, Shota
    Osumi, Hiroki
    Ogura, Mariko
    Wakatsuki, Takeru
    Ooki, Akira
    Shinozaki, Eiji
    Chin, Keisho
    Yamaguchi, Kensei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 265 - 265
  • [5] Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study
    Salgado, Mercedes
    Reboredo, Margarita
    Carlos Mendez, Juan
    Quintero, Guillermo
    Luz Pellon, Maria
    Romer, Carlos
    Jorge, Monica
    Fernandez Montes, Ana
    Valladares-Ayerbes, Manuel
    Ramos, Manuel
    Varela, Silvia
    Angel Alonso, Miguel
    [J]. ANTICANCER RESEARCH, 2013, 33 (09) : 4089 - 4096
  • [6] Margetuximab: An active alternative for later-line therapy in patients with HER2-positive advanced breast cancer
    Zhou, Yunxiang
    Wang, Xiaojia
    Chen, Yiding
    [J]. MEDCOMM, 2023, 4 (04):
  • [7] Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study
    Ryosuke Kumanishi
    Shigenori Kadowaki
    Seiichiro Mitani
    Tomohiro Matsushima
    Takatsugu Ogata
    Yukiya Narita
    Toshiki Masuishi
    Hideaki Bando
    Masahiro Tajika
    Hisateru Yasui
    Hiroki Hara
    Kei Muro
    [J]. International Journal of Clinical Oncology, 2023, 28 : 756 - 763
  • [8] Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study
    Kumanishi, Ryosuke
    Kadowaki, Shigenori
    Mitani, Seiichiro
    Matsushima, Tomohiro
    Ogata, Takatsugu
    Narita, Yukiya
    Masuishi, Toshiki
    Bando, Hideaki
    Tajika, Masahiro
    Yasui, Hisateru
    Hara, Hiroki
    Muro, Kei
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (06) : 756 - 763
  • [9] Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis
    Rizzo, Alessandro
    Mollica, Veronica
    Ricci, Angela Dalia
    Maggio, Ilaria
    Massucci, Maria
    Limpe, Fabiola Lorena Rojas
    Di Fabio, Francesca
    Ardizzoni, Andrea
    [J]. FUTURE ONCOLOGY, 2020, 16 (02) : 4409 - 4418
  • [10] Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
    Yang, Qiong
    Yin, Chenxi
    Liao, Fangxin
    Huang, Yuanyuan
    He, Wenzhuo
    Jiang, Chang
    Guo, Guifang
    Zhang, Bei
    Xia, Liangping
    [J]. ONCOTARGETS AND THERAPY, 2015, 8 : 2407 - 2413
12345